# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-14T14:08:02.728997

---

**Idea Fidelity**

The paper largely follows the manifest’s central ambition: it uses IPEDS institution-level data to study the effects of the PBF 2.0 wave on degree production and enrollment composition, applies modern staggered DiD methods, and emphasizes the cream‑skimming margin identified through minority shares in enrollment. However, several promised elements are missing or only sketched. (i) The manifest explicitly proposes exploiting granular demographic (Pell, race, part‑time) and CIP‑level completions to test the cream‑skimming and field‑shifting hypotheses, but the paper stops at aggregate minority shares and does not engage with Pell status, part‑time enrollment, or program composition. (ii) The idea envisioned exploiting within‑state variation (public vs. private institutions) as an auxiliary identification strategy; instead, the paper relegates this to a placebo check, without fully incorporating a public/private triple difference to absorb state‑specific shocks. (iii) The manifest emphasized testing dose heterogeneity (share of funding at stake) and potential equity bonuses; the paper only briefly notes heterogeneous point estimates in a robustness table but does not systematically model dose or metric variation. The project still captures the core research question, but it falls short of the richer empirical agenda outlined in the manifest.

---

**Summary**

This paper studies whether the adoption of PBF 2.0 formulas affected bachelor's degree completions and enrollment composition in treated states’ public four-year institutions. Using a Callaway–Sant’Anna staggered DiD on 676 institutions (2003–2022), it finds a precise null on completions and graduation rates but a statistically significant decline (~1.6 percentage points) in minority enrollment share, interpreted as evidence of cream-skimming. A private‑institution placebo provides some reassurance that the estimates are not driven by statewide shocks.

---

**Essential Points**

1. **Parallel trends and the never-treated counterfactual.** The strategy hinges on never-treated states providing a valid counterfactual, but the paper presents only a brief summary (“pre-treatment coefficients centered near zero”) without showing event-study plots or formally testing differential trends. Given that PBF adopters tend to be states with more aggressive higher-education agendas and different economic trajectories, the credibility of the comparison requires more documentation. Please present event-study graphs (with pre‑ and post‑treatment coefficients for the Callaway–Sant’Anna estimator) for the main outcomes, include formal tests (e.g., joint F-tests on pre-trends), and describe any differences in pre-trends between PBF and non-PBF states.

2. **Limited evidence for the cream-skimming mechanism.** The main empirical claim about cream‑skimming rests on a decline in aggregate minority enrollment share; yet the manifest promised richer tests (Pell receipt, part-time status, completion shares by race/CIP). Minority share alone could decline because minority students shift between campuses or because the pipeline changes outside the institution’s control. Without parallel evidence that at-risk groups (e.g., Pell recipients, part-time students, fields with low completion rates) are being de-emphasized, the mechanism remains speculative. Please expand the composition analysis to include at least one additional margin (Pell share, part-time enrollment, or 2‑year transferer share) and show whether completions by disadvantaged groups also decline, ideally using the same Callaway–Sant’Anna estimator.

3. **Insufficient integration of within-state variation and dose heterogeneity.** The manifest envisioned a stronger identification strategy that treats private institutions as an internal control and leverages variation in funding share to assess treatment intensity. The current paper treats the private institutions only as a placebo, leaving “within-state” and “dose” variation under‑utilized. Incorporating a triple-difference (public vs. private within treated states) would better control for contemporaneous state-level shocks (especially if policy adoption coincides with other reforms). Likewise, the dose-response evidence is limited to a robustness table with imprecise point estimates. Please formalize a triple-difference estimator to demonstrate that PBF effects are concentrated among public institutions controlling for state-specific shocks, and estimate a more detailed model of treatment intensity (e.g., interact treatment with the percentage of funding tied to outcomes or the presence of equity bonuses).

---

**Suggestions**

1. **Provide richer diagnostics for identification.** In addition to event-study plots, report the distribution of treatment timing across cohorts and whether pre-treatment trends differ by cohort, sector size, or baseline minority shares. The manifest suggested a “smoke test log” and rich data description; the paper could include a table showing how treated states compare to never-treated states on pre-treatment outcome trends, economic conditions, and higher-education capacity. Also consider controlling flexibly for time-varying state characteristics (e.g., unemployment, tuition caps, state GDP per capita) to reduce residual confounding that simple fixed effects may not absorb.

2. **Enhance the composition analysis using IPEDS granularity.** IPEDS contains Pell receipt, part-time/full-time status, and gender, which are directly relevant to cream-skimming. Even if some of these have shorter time-series or more missingness, presenting results for Pell share or part-time share would bolster the narrative. Similarly, examining whether minority shares decline more in high-stakes PBF states (those tying ≥20% of funding or including equity bonuses) would speak to the theory that stronger incentives elicit strategic enrollment adjustments. Consider an outcome like “Pell share of fall enrollment” as a complement to the minority share.

3. **Reconcile the null on completions with the literature.** The paper interprets the null via Goodhart/holmstom, but additional context would help. For example, how do the point estimates compare to those in Hillman et al. (2015) or Umbricht et al. (2017)? Are the null findings driven by low-power (few treated institutions per cohort) or by actual estimates close to zero? Providing confidence intervals in percentage terms (e.g., ruling out >X% increases) would clarify the policy implication. Additionally, consider whether lagged effects might exist—are there suggestive differences in cohorts observed 3+ years post-treatment compared to earlier? Panel length varies across adopters, so showing how effects evolve with “years since adoption” would be informative.

4. **Improve reporting of robustness checks.** The robustness table currently presents TWFE estimates without the heterogeneity-robust Callaway–Sant’Anna counterparts for the same specifications. Given the emphasis on modern DiD, it would be helpful to report the Callaway–Sant’Anna ATT for the triple-difference, dose, and restricted-cohort specifications, or at least explain why TWFE suffices for those checks. Also, the appendix mentions “anticipation” but no empirical results are shown—please report an anticipation model (e.g., shifting treatment backwards by one year) to demonstrate robustness.

5. **Clarify sample choices and missing data.** The final sample is 676 institutions, yet earlier descriptions mentioned 727 institutions. Explain the attrition (missing years, incomplete surveys) and whether it is related to treatment status. For graduation rates, only 577 institutions are available; mention whether this missingness is balanced across treatment groups. Transparency on these points would enhance confidence in the findings.

6. **Address potential spillovers or policy bundling.** PBF adoption often came with broader reforms (e.g., increased performance reporting, intrusive state oversight). If data permit, consider controlling for or discussing concurrent policies that might confound the results—especially since the paper attributes changes to PBF alone. Even if additional controls are unavailable, acknowledging and discussing potential co-treatments helps contextualize the estimates.

Overall, the paper tackles an important question with rich data and modern methods. Strengthening its identification diagnostics, expanding the compositional evidence, and fully executing the research agenda laid out in the manifest will turn the precise null on completions and suggestive evidence of cream-skimming into a compelling contribution.
